What GAIASO Theranostics does

GAIASO Theranostics is an Australian, privately held biotechnology company incorporated in 2025 and headquartered in North Melbourne, Victoria, that is developing precision radiotheranostics—pairs of diagnostic imaging agents and targeted radiotherapies—specifically designed for women's cancers. Its pipeline targets breast, ovarian, endometrial and cervical cancers, with a longer-tail optionality in other female-biology-impacted cancers, addressing gaps such as late diagnosis, diffuse microscopic tumour burden, limited precision therapies with off-target toxicity, and relapse. The company's intended 'See-Select-Treat' workflow combines whole-body disease mapping, molecular-imaging-based patient selection, and targeted radiotherapeutics intended to be combinable with standard chemo, ADCs, biologics, immuno-oncology agents and maintenance regimens.

The technical platform is built on modular molecular scaffolds that allow rapid re-targeting across tumour antigens and isotope pairings, with target selection grounded in female-cancer biology, ligand engineering for tumour penetration and stability, and paired diagnostic/therapeutic isotope selection. The targeting layer is supplied by Affilin® scaffold proteins licensed from Navigo Proteins (Germany)—small, non-glycosylated, human-origin engineered proteins positioned for deep tumour penetration and low immunogenicity—and the Navigo CEO sits on GAIASO's board, embedding the technology partner into governance.

The business is pre-revenue and pre-commercial: GAIASO is currently in startup phase, not trading, engaged in research and development and capital-raising activities preparatory to its proposed business, with future monetisation expected via sales of approved radiotheranostic products and licensing once regulatory approval is obtained. Distribution channels are not yet established; planned go-to-market involves clinical trials, regulatory approvals and collaboration with clinicians, scientists and patients, with eventual sales envisaged direct-to-hospital/cancer-centre channels supplemented by partnerships with established radiopharmaceutical distributors. The company operates from a single Australian site (11–50 employees), is led by Dr Tracey Brown (CEO, appointed September 2025) under Chair Prof. Jill Hennessy, and the board is staffed by veterans of Telix Pharmaceuticals and ITM Isotope Technologies Munich together with the Navigo Proteins CEO, signalling a deliberate rent-a-team strategy from the most successful radiopharma franchises globally.

Name

GAIASO Theranostics

Legal name

GAIASO Theranostics Pty Ltd

Website

https://gaiasotheranostics.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Pre-revenue Australian biotech developing precision radiotheranostics—paired diagnostic imaging agents and targeted radiotherapy—for breast, ovarian, endometrial and cervical cancers using a modular molecular-scaffold platform and Navigo Proteins' Affilin® targeting technology.

Ownership category

akta.pro rank

Product category

Radiopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (62151)

SIC

Biological Products, (No Disgnostic Substances) (2836), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)

akta.pro secondary industry

Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB)

Keywords

• Precision radiotheranostics
• Women's cancer therapeutics
• Targeted radionuclide therapy
• Radiopharmaceutical development
• Molecular imaging diagnostics

Headquarters

HQ city

North Melbourne

HQ country

Australia

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Future Radiotheranostic Product Sales: GAIASO Theranostics is currently in its startup phase and not yet trading. The company is engaged in research and development and capital raising activities, preparing for future commercialization of precision radiotheranostic products for women's cancers. The ultimate goal is to design and develop next-generation theranostic products that will be commercialized globally upon regulatory approval.

Go-to-market motion1 record

Marketing channels4 records

Core offering

GAIASO Theranostics is developing a modular radiotheranostics platform that combines diagnostic molecular imaging with targeted radiotherapy for women's cancers. The platform pairs imaging agents with therapeutic isotopes across breast, ovarian, endometrial, and cervical cancer programs using a See-Select-Treat approach. It also incorporates Affilin® protein technology licensed from Navigo Proteins for precision tumour targeting, and is currently in pre-clinical R&D ahead of future global commercialization.

Product overview

GAIASO Theranostics operates as a unified precision radiotheranostics platform purpose-built for female cancers. The core offering consists of the GAIASO Theranostics Platform, a modular molecular scaffold system that integrates diagnostic imaging with targeted radiotherapy across breast, ovarian, endometrial, and cervical cancers. This platform leverages licensed Affilin® Technology from Navigo Proteins for precision protein targeting, combining target selection informed by female cancer biology, ligand engineering for tumour penetration, and isotope pairing for both imaging clarity and therapeutic effect.

Differentiator

Problem solved

Functional benefit

Products and services

• GAIASO Theranostics Platform Modular theranostics platform designed for female cancers that integrates diagnostic molecular imaging with targeted radiotherapy. Supports a See-Select-Treat clinical workflow covering whole-body disease mapping, precision patient selection based on tumour biology, and targeted radiotherapeutics delivery. Under development by GAIASO Theranostics Pty Ltd for breast, ovarian, endometrial, and cervical cancer programs, with planned global commercialization upon regulatory approval.

Segments5 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• PreMIT (Australia)coreStrategic or Co-development PartnerPreMIT is listed as a key collaboration partner on GAIASO's website. PreMIT (Precision Medicine Institute of Theranostics) is an Australian organization focused on precision medicine in theranostics. The partnership represents GAIASO's building on key collaborations with Australian partners in the theranostics space.
• Navigo Proteins (Germany)coreTechnology or IntegrationNavigo Proteins provides the Affilin technology platform to GAIASO for developing next-generation targeted therapeutic proteins. Affilins are small, human-origin scaffold proteins engineered for precision targeting in radiotheranostics. Navigo Proteins CEO Dr. Henning Afflerbach also serves as Non-Executive Director on GAIASO's board. The partnership enables GAIASO to utilize Affilin molecules for deep tumour penetration and high-affinity binding.
• MTIC - Melbourne Theranostic Innovation Centre (Australia)coreStrategic or Co-development PartnerMTIC (Melbourne Theranostic Innovation Centre) is listed as a key collaboration partner. GAIASO's Chair, Prof. Jill Hennessy, serves as a Director of the Melbourne Theranostic Innovation Centre. The partnership leverages Australia's theranostic research and development ecosystem, providing access to specialized equipment and expertise for radiopharmaceutical development.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Telix Pharmaceuticals: Australian-headquartered radiopharmaceutical company developing diagnostic and therapeutic agents across oncology, including in prostate and other solid tumours. Directly comparable as an Australian-listed radiopharma platform; multiple GAIASO executives and board members are Telix alumni, including CEO Dr Tracey Brown and CFO Doug Cubbin.
• ITM Isotope Technologies Munich: Germany-based radiopharmaceutical company producing medical radioisotopes and developing targeted radiodiagnostics and radiotherapeutics. Closely comparable given GAIASO's theranostic model; ITM's founder Oliver Buck and CBO Dr Sebastian Marx both serve as GAIASO NEDs.

Broad incumbents

• Novartis (Pluvicto / Lutathera franchise): Large pharmaceutical company that commercialised Lutathera and Pluvicto, the leading radioligand therapies in neuroendocrine tumours and prostate cancer. Relevant as the dominant commercial reference point for theranostic paired Dx/Tx in oncology against which GAIASO's pipeline will be benchmarked.
• Lantheus Holdings: US-based radiopharmaceutical company with a broad diagnostics and emerging therapeutics portfolio (e.g., PNT2002/Pluvicto-class assets and prostate cancer imaging). Comparable as a publicly traded, scaled radiopharma platform targeting oncology indications.
• Bayer (Radiopharmaceuticals / Algeta heritage): Diversified pharmaceutical company with an active radiopharmaceuticals franchise rooted in Xofigo (radium-223). Comparable as a major incumbent investing in paired diagnostic/therapeutic radioligand approaches in oncology.
• Curium Pharma: Global nuclear medicine company producing radiodiagnostics and radiotherapeutics across multiple isotopes and indications. Comparable as a vertically integrated radiopharma manufacturer with both imaging and therapy product lines.

Emerging players

• POINT Biopharma: Clinical-stage radiopharmaceutical company developing radioligand therapies across multiple solid tumours prior to its announced acquisition by Eli Lilly. Comparable as a pre-commercial radioligand peer with a similar theranostic development model in oncology.
• Fusion Pharmaceuticals: Clinical-stage radioconjugate company developing targeted alpha therapies, acquired by AstraZeneca. Comparable as a pre-commercial radiopharma peer developing paired imaging/therapy agents in oncology.
• RayzeBio: Clinical-stage radiopharmaceutical company developing actinium-225 alpha-emitter therapies for solid tumours, acquired by Bristol Myers Squibb. Comparable as an oncology-focused radiopharma peer at a similar stage of maturity to GAIASO.

Others

• Navigo Proteins: German protein-engineering company developing the Affilin scaffold platform, which GAIASO has licensed for its radiotheranostics programme. Included as an enabling partner/comparable rather than a competitor — GAIASO's targeting scaffold derives directly from Navigo's technology, and Navigo's CEO sits on GAIASO's board.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/gaiaso-theranostics

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GAIASO Theranostics